return to warmwell.com


Press release from Fort Dodge Feb 5 2008

5 February 2008

Fort Dodge Receives Temporary Authorisation for Use of Zulvac 1 Bluetongue Vaccine in France

Amsterdam, 5 February 2008 – Fort Dodge Animal Health, a division of Wyeth (NYSE: WYE), has received temporary authorisation for the use of its Zulvac® 1 vaccine against serotype 1 Bluetongue (BTV-1) in bovines and sheep in France. This authorisation comes a month after its Bluetongue vaccines were given similar authorisation for use in Spain.

France, a major producer of cattle and sheep, has witnessed the rapid spread of Bluetongue serotype 8 since August 2006 when the first case was reported in Northern France. Since then, the disease has spread south, affecting almost the entire country, including Brittany, Burgundy, Limousin and Morvan, which are important cattle producing areas. In the meantime, Bluetongue serotype 1 has entered the country at Biarritz in the southwest corner, close to the Spanish border.

Fort Dodge is the first to be appointed by the French authorities to supply the serotype 1 vaccine. The company expects to start delivering the vaccine in the coming months.

"Bluetongue is a serious problem in France as in the rest of Europe and we are delighted Zulvac 1 has received temporary authorisation. We believe it can make a major contribution to helping control the disease in France," says Marc Snacken, Business Manager Livestock, Fort Dodge Europe, Africa and Middle East.

Fort Dodge Animal Health is a leading manufacturer and marketer of animal health products for the companion animal, equine, livestock, swine and poultry industries in North America and international markets. Key products include ProMeris®, ProMeris Duo®, Duramune®, Fevaxyn®, Duvaxyn®, Suvaxyn®, Poulvac®, Cydectin® and Equest® and Equest Pramox®.

Note to editors:

Fort Dodge Animal Health is a division of the Wyeth Corporation, one of the largest research-based pharmaceutical and healthcare products companies in the world.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialisation (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

For further information:

Rebecca George

George PR

Tel: 01449 737281/07974 161108


2 January 2008

Spanish Ministry of Agriculture Awards Fort Dodge a Silver Award for Agricultural Merit for Bluetongue Disease Control

The Spanish Ministry of Agriculture has awarded vaccine manufacturer Fort Dodge a Silver Award for Agricultural Merit in recognition of its work to develop a vaccine for Bluetongue Serotypes 4 and 1. The award was presented by Minister for Agriculture, Fish and Food Elena Espinosa to Juan Carlos Castillejo, Fort Dodge Country Manager for Spain, on 4 December 2007 during the Celebration of the National Constitution.

Fort Dodge is one of the first companies to be appointed by the Spanish authorities to produce the serotype 1 vaccine. The vaccines, Zulvac® 4 and Zulvac® 1, will be produced at the company’s manufacturing facilities in Olot, Spain. Zulvac 4 has already been granted an emergency Marketing Authorisation while Authorisations for Zulvac 1 are in the process of being obtained.

"Given the challenges Bluetongue disease has created for farmers in southern and northern Europe, we have focused considerable effort and resources on the development of vaccines," says Marc Snacken, Business Manager Livestock, Fort Dodge Europe, Africa and Middle East. "We are honoured that the Ministry of Agriculture has recognised our achievements in this way and we look forward to working closely with the Spanish authorities and veterinary professionals to combat Bluetongue in the months ahead."

Elena Espinosa commented: "Fort Dodge has shown great dedication to developing a vaccine against Bluetongue Serotypes 1 and 4. Its work has helped Spain to set an example to other European companies in the treatment of Bluetongue using inactivated vaccines. It has benefited everyone in Spain."

Fort Dodge Animal Health is a leading manufacturer and distributor of animal health products for the companion animal, equine, livestock, swine and poultry industries in North America and international markets with key products including ProMeris, ProMeris Duo, Duramune, Fevaxyn, Duvaxyn, Suvaxyn, Poulvac, Cydectin and Equest and Equest Pramox.

Picture shows:

Elena Espinosa, Spanish Minister for Agriculture, Fish and Food, (right) presenting the Silver Award to Juan Carlos Castillejo, Fort Dodge Country Manager for Spain.

Note to editors:

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialisation (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

For further information:

Rebecca George

George PR

Tel: 01449 737281/07974 161108